Hereditary cancer panel is a predesigned panel for targeted resequencing assay utilizing amplicon sequencing technology by Illumina system, designed to detect inherited mutations and not suitable for the detection of other types of mutations in acquired cancers. The panel covers a total of 37 genes associated with cancers of the breast, ovary, uterus, prostate, gastric and colorectal, etc.
CD Genomics utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations in hereditary cancer-associated genes. Targeted NGS sequencing facilitates sequencing multiple genes and samples in a single and cost-effective assay.
Coding Sequence (CDS):
We provide customized bioinformatics analysis including:
CD Genomics provides the accurate and cost-effective hereditary cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for hereditary cancer panel sequencing is outlined below.
For more information about the hereditary cancer panel or need other amplification requirements, please contact us.